HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


OTC Allergy Switch Approved For Bayer In US

Azelastine 0.15% Nasal Antihistamine Branded Astepro Allergy Is First-In-Class Switch

Executive Summary

CDER approves Bayer Healthcare’s azelastine 0.15% nasal antihistamine indicated for seasonal and perennial allergic rhinitis in adults and children 6 and older. Bayer says Astepro Allergy is first steroid-free antihistamine for allergies available OTC in the US and the first indicated for indoor and outdoor allergy relief.

You may also be interested in...

Sildenafil, Tadalafil Among Big Hitters On Upcoming German Switch Committee Agenda

Possible OTC switches of erectile dysfunction drugs sildenafil and tadalafil, as well as azelastine and fluticasone propionate combination nasal sprays and migraine drug rizatriptan, are on a packed agenda for the next meeting of the German Expert Committee on Prescription.

Bayer Blames Macroeconomic Pressures For Lower Volumes In Q1

Inflationary pressures and supply constraints led to volume declines at Bayer Consumer Health in Q1. However, price rises offset these headwinds helping the business to post a 4% rise in sales.

Alternative Smoking Cessation Drug Cytisine On 2023 German Switch Committee Agenda

Low-cost alternative smoking cessation drug cytisine is under consideration by Germany's independent switch committee in January, alongside azelastine and fluticasone propionate in combination for intranasal use, olopatadine for ophthalmic use and bilastine (10mg) for oral use.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts